Analyst Ratings for Relmada Therapeutics Inc (RLMD)
RLMD Rating Summary
RLMD Price Target Summary
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$10.25 (+130.3%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 52%
Avg. $ Target:
$10.25 (+130.3%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 52%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Lucid Capital Markets | Christopher Liu | New Coverage | Buy (N/A) |
14.00 (N/A) |
4.56 (4.45) |
-2.41% | Details |
| 1/23/2026 | Leerink Partners | Marc Goodman | Upgrade | Outperform (Market Perform) |
8.00 (N/A) |
3.96 (4.45) |
12.37% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
